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Background: Evidences indicate that inflammatory process plays pivotal role in tumor disease. Soluble epoxide
hydrolase inhibitors (sEHIs) have been shown to participate in anti-inflammation and tumorigenesis by protecting
epoxyeicosatrienoic acids (EETs). Although we have previously revealed some effects of t-AUCB on glioma in vitro,
further investigations are needed to demonstrate its effects on glioblastoma growth in vivo and how to strengthen
its antitumor effect.
Methods: CCK-8 kit was used to test cell growth. Cell migration capacity was performed by wound healing assays.
Transwell assay was used to test cell invasion potency. Cell-cycle analysis and cell apoptosis was performed by flow
cytometry. The activity of caspase-3 in cells was measured using caspase-3 activity assay kits. Total RNA was extracted
from cells lysated by TRIzol reagent. qRT-PCR was performed by ABI 7500 fast RT- PCR system. Lipofectamine RNAiMAX
Transfection Reagent (Invitrogen) was used for siRNA transfection. Western blootting was used to test protein expression.
Tumor cell xenograft mouse models were used for in vivo study. The SPSS version 17.0 software was applied for statistical
analysis.
Results: Our data shown that t-AUCB inhibits cell proliferation, migration and invasion and induces cell cycle G1 phase
arrest in vitro but induces no cell apoptosis; increased Hsp27 activation and following COX-2 overexpression confer
resistance to t-AUCB treatment in glioblastoma both in vitro and in vivo; quercetin sensitizes glioblastoma to t-AUCB
by dual inhibition of Hsp27 and COX-2 in vitro and in vivo.
Conclusions: These results indicate that combination of t-AUCB and quercetin may be a potential approach to treating
glioblastoma.
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Glioblastoma is the most common primary malignant
tumor of the central nervous system in adults, which is
highly aggressive and neurologically destructive. Despite
the advances in surgery, radiotherapy and chemotherapy,
survival time for patients with glioblastoma has remained
at less than one year, not to mention the patients’ pain
and heavy economic burden [1–5]. In view of the impossi-
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radiotherapy, we suggest developing more efficient agent
or combination of agents with great therapeutic effects
and fewer side effects to treat glioblastoma or apply as
postoperative adjuvant via circulatory system.
Recently, inflammation has been widely studied in malig-
nant tumors and considered to participate in networks of
activated signaling cascades, transcription factors and their
coordinated interactions and promote tumorigenesis [6–8].
It could be effective therapy against malignant tumors
to inhibit inflammation and then target inflammation-
mediated transcription-factor interplay and signaling path-
ways [9]. Epoxyeicosatrienoic acids (EETs), a metabolite
converted from arachidonic acid (ARA) by cytochromestributed under the terms of the Creative Commons Attribution 4.0 International
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with antihypertensive, anti-inflammatory, analgesic, and
cardioprotective effects [10]. EETs are easily to be hydro-
lyzed in vivo by soluble epoxide hydrolase (sEH) to form it’s
less active or inactive metabolite dihydroxyeicosatrienoic
acids (DHETs). Thus, various pharmacological inhibitors of
sEH (sEHIs) have been developed to stabilize endogenous
EETs and exert therapeutic effects [11]. Several studies have
demonstrated that sEH play critical roles in angiogenesis
and tumorigenesis, indicating the antitumor effects of
sEHIs [12–14].
Our previous study has determined that t-AUCB, an
improved sEHi synthesized and kindly provided by Prof.
Hammock and his team, inhibits human glioblastoma cell
growth, although cells then acquire apoptosis-resistance
to t-AUCB via Hsp27 activation [15]. Considering the well
proved antihypertensive, anti-inflammatory and analgesic
effects of sEHIs which may greatly alleviate the pain of the
patients, we suggest sEHIs may be a potential agent for
glioblastoma treatment and worth further study. Recently,
Prof. Hammock and his team demonstrated that a com-
bination of COX-2 inhibitor and sEH inhibitor (t-AUCB)
synergistically inhibits primary tumor growth. They also
developed a COX-2/sEH dual inhibitor, PTUPB, which
significantly suppresses primary tumor growth and metas-
tasis [16]. In present study, we study the effects and in-
teractions of Hsp27 inhibitor, quercetin, and t-AUCB on
glioblastoma cells, and demonstrate that combination of
quercetin and t-AUCB synergistically inhibits glioblast-
oma growth in vitro and in vivo. We also unexpectedly
reveal that quercetin suppress COX-2 expression by




The sEH inhibitor t-AUCB was granted from Professor
Bruce D. Hammock (Department of Entomology and UCD
Cancer Research Center, University of California, Davis,
CA, USA) [17], and the chemical constitution of t-AUCB
was shown in Fig. 1a. The p38 MAPK inhibitor SB203580
and Hsp27 inhibitor quercetin were both purchased from
Sigma-Aldrich (St. Louis, MO, USA). All of agents were
dissolved in dimethyl sulfoxide (DMSO). The concentration
which was never exceeded 0.1 % (v/v) was diluted in
serum-supplemented medium immediately before use. For
cell growth assays, cells were treated with t-AUCB in differ-
ent final concentrations of 0, 10, 50, 100, 150, 200, 300 or
400 μM, and quercetin in final concentrations of 0, 5, 15,
30 or 60 μM. For p38 MAPK inhibition, cells were treated
with SB203580 in 20 μM as we have described previ-
ously [15]. For Hsp27 inhibition, cells were treated with
quercetin in 30 μM. In animal experiments, the mice
were treated with t-AUCB (3 mg · kg−1 · d−1) by oralgavage or/and injected intraperitoneally with 20 mg/kg
quercetin every day.
Cell culture
Human glioblastoma cell lines U251 and U87 were pro-
vided by ATCC (American Type Culture Collection) as we
used previously [15]. All cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with
10 % fetal bovine serum (FBS) and 1 % penicillin and
streptomycin (complete medium). Cells were maintained
at 37 °C in a humidified atmosphere of 95 % air and 5 %
CO2.
Cell growth assay
Cell growth ability was exhibited by the cell counting
kit-8 (CCK-8) from Dojindo Laboratories (Kumamoto,
Japan). Cells were transplanted into a 96-well plate with
density of 5000 cells/well and then treated differently.
Cells were cultured in humidified incubator containing
5%CO2 and 95 % air. 48 hours later, culture medium in
each well was discarded, and 100 μl fresh serum-free
medium contained 10 μl CCK-8 solution was added into
each well. After two hour incubation, the optical density
value (absorbance) was recorded at 450 nm using an
enzyme-linked immunosorbent assay plate reader (Bio-Rad
Laboratories, Inc., Berkeley, CA, USA).
Cell migration and invasion assays
Cell migration capacity was performed by wound healing
assays. U251 cells were transplanted in 6-well plates.
The scratch wounds were generated with a pipette tip.
Cells were washed with PBS and incubated in a serum-
free medium. 16 hours after scratching, wounds were
fixed and photographic images were collected. Trans-
well assay was used to test cell invasion potency. U87
cells were transplanted in 24-well BioCoat Matrigel
Invasion Chambers (8 μm pore size, Corning) with
matrigel-coated in serum-free DMEM. Conditioned
medium were cultured into the lower chambers like
chemo-attractants. After incubation for 24 hours, the
cells from upper surface of filters were scraped by a cot-
ton swab, whereas matrigel were penetrated by other
cells which adherent to the bottom of membrane.
Methanol was used as fixed solution and 0.1 % crystal
violet were used to stain.
Cell-cycle analysis by flow cytometry
The cells were seeded in 10 cm culture dishes, then treated
separately after adherence for 48 h at 37 °C in humidified
incubator. Cells were collected followed by trypsinization,
centrifuged (3500 rpm for 5 min), and washed twice
with PBS. 1 ml 70 % ethanol was used as fixed solu-
tion, precipitated by centrifugation (3500 rpm for
5 min), and propidium iodide was used for staining
Fig. 1 t-AUCB inhibits cell proliferation. a: The chemical constitution of t-AUCB. b: The percentage of OD value in t-AUCB treated cells compare with
control represent the relative cell viability (%) in CCK-8 assay. U87 and U251 cells were treated with vehicle control (0 μM), 10 μM, 50 μM, 100 μM, 150 μM,
200 μM, 300 μM or 400 μM t-AUCB for 48 h. t-AUCB suppresses cell proliferation in a concentration-dependent manner since 100 μM (*P< 0.05). 150 μM
to 400 μM t-AUCB causes more efficient cell growth inhibition (**P< 0.01)
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FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA).Apoptosis analysis by flow cytometry
For apoptosis analysis, the cells were seeded in 10 cm
culture dishes, then treated separately after adherence
for 48 h at 37 °C in humidified incubator. Cells were col-
lected followed by trypsinization, centrifuged (3500 rpm for
5 min), and washed twice with PBS, the supernatant was
discarded. The pellet was incubated away from light for
15 min at room temperature with Annexin V-fluorescein
isothiocyanate (FITC) and propidium iodide (PI) before
analysis with a FACSAria III flow cytometer (BD Biosci-
ences, San Jose, CA, USA) according to the standard
protocol.Caspase-3 activity assay
As we previously described [15], the activity of caspase-3
in cells was measured using caspase-3 activity assay kits
from Millipore (Kankakee, IL, USA) following the manu-
facturer’s instructions. Absorbance was represented the
level of caspase-3 activity and tested at 405 nm in a micro-
titer plate reader. In a word, cell samples were collected
and resuspend in chilled 1 × Cell Lysis Buffer for 10 min,
then centrifuged at 4 °C for 5 min in a microcentrifuge
(10,000 × g). The supernatants were subsequently added
into a 96-well plate and incubated with Ac-DEVD-pNA in
the working solution containing caspase-3 substrate for
1 h at 37 °C. Fold-increase in caspase-3 activity was deter-
mined by comparing the absorbance from an apoptotic
sample with an un-induced control after subtracting the
background value reading from cell lysates and buffers.
Each determination was performed in triplicate.
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Total RNA was extracted from cells lysated by TRIzol re-
agent (Invitrogen, USA) according to the manufacturer’s
instructions. The quality and quantity of the RNA purity
were assessed by spectrophotometer and standard electro-
phoresis. cDNA was synthesized from 1 μg RNA and re-
verse transcribed using PrimerScript™ RT reagent Kit
(Takara). The expression levels were quantified by Taq-
man™ Assay kit (Applied Biosystems, USA) in according
with the manufacturer’s instructions. The sequences of
primers for the COX-2 were as follows: forward: 5’-
ATACCAAAACCGCATTGCCG-3’; reverse: 5’- TCTAAC
TCCGCAGCCATTTC-3’. Expression of GAPDH was
performed as normalized. The sequences of primers for
GAPDH were as follows: forward: 5’-GGAAGGTGAAGG
TCGGAGTC-3’; reverse: 5’-GTCTTCTGGGTGGCAGT-
GAT-3’. Each reaction was performed by ABI 7500 fast RT-
PCR system in triplicate. The expression of gene was
defined based on the threshold cycle (Ct) value. The relative
expression of the studied samples were assessed using the
comparative delta-delta Ct method (TaqMan Relative
Quantification Assay software), adjusted to GAPDH ex-
pression level.RNA interference
Cells were grown in 10-cm culture dish and transiently
transfected with Hsp27 or COX-2 specific small interfer-
ing RNA (siRNA). The siRNA oligos of Hsp27 (sc-29350),
COX-2 (sc-270376) and the negative control siRNAs were
purchased from Santa Cruz Biotechnology (Dallas, TX,
USA). Lipofectamine RNAiMAX Transfection Reagent
(Invitrogen) was used for siRNA transfection according to
the manufacturer’s protocol.Western blot analysis
Cell protein was lysates in ice-cold RIPA buffer (Beyotime
Institute of Biotechnology, Shanghai, China) containing
with Phenylmethanesulfonyl fluoride (PMSF) and protease
inhibitor cocktail. The procedure of Western Blot was
described as before [15]. The whole cell lysates were
separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to a polyvinylidene fluoride mem-
brane (Millipore Corporation, Bedford, MA, USA). All
membranes were probed with primary antibodies after 4 °C
overnight, and followed by incubation with secondary anti-
body. Proteins were visualized with chemiluminescence
luminol reagents (Beyotime Institute of Biotechnology,
Shanghai, China). Antibodies against β-actin (#3700), c-
Myc (#9402), Cdc25A (#3652), Cyclin D1 (#2978), CDK4
(#12790), CDK6 (#3136), MCM3 (#4012), MCM7 (#3735),
COX-2 (#12282), Hsp27 (#2402), p-Hsp27 (Ser78) (#2405)
were purchased from Cell Signaling Technology (Beverly,
MA, USA). Public software ImageJ (National Institutes ofHealth, USA) was used to quantify the densitometry of the
immunoblotting bands.
Tumor cell xenograft mouse models
Animal experiments protocols were approved by the
Institutional Animal Committee of Jinling Hospital.
The BALB/c nude mice (male at 5 to 6 weeks old)
were obtain from Department of comparative medi-
cine (Jinling Hospital, China) and maintained in spe-
cific pathogen-free (SPF) conditions. Approximately
1.0 × 106 U87 cells were transplanted subcutaneously
to develop a mouse xenograft model of human glio-
blastoma. Once tumor diameter reach to 2-4 mm, the
treatment with quercetin or/and t-AUCB was adminis-
tered. The length and width of the tumors were
measured every other day using vernier caliper, and
tumor volume was calculated (tumor volume = 1/2 ×
length × width2). The mice were treated with t-AUCB
(3 mg · kg−1 · d−1) by oral gavage or/and injected
intraperitoneally with 20 mg/kg quercetin every day.
14 days after treatment, all tumors retrieved from
animals were measured, weighed and submitted for
western blot analysis for the expression of Hsp27, p-Hsp27
and COX-2.
Statistical analysis
All experiments were replicated in triplicate at least. The
SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA)
was applied for statistical analysis. Comparisons between
treated groups and vehicle control were performed using
independent t test, and expressed as mean ± standard devi-
ation (SD). P < 0.05 were considered statistically significant.
Results
t-AUCB inhibits cell proliferation, migration and invasion
The CCK-8 assay kit was used to test the cell proliferation.
Human glioblastoma cell lines U251 and U87 were treated
with vehicle control (DMSO), 10 μM, 50 μM, 100 μM,
150 μM, 200 μM, 300 μM or 400 μM t-AUCB for 48 h. As
the results shown in Fig. 1, t-AUCB suppresses cell prolifer-
ation in a concentration-dependent manner since 100 μM
(P < 0.05). 150 μM to 400 μM t-AUCB causes more effi-
cient cell growth inhibition (P < 0.01). The IC50 of t-AUCB
is 347.38 μM (to U87 cells) and 305.05 μM (to U251 cells).
Cell migration was evaluated by wound healing ana-
lysis. U251 cells were planted and treated with vehicle
control (DMSO), 10 μM, 100 μM or 200 μM t-AUCB
for 16 h. 100 μM or 200 μM t-AUCB treatment sup-
presses the scratched cell monolayer healing, whereas
10 μM t-AUCB has no effect (Fig. 2a and b).
Cell invasion was analyzed using matrigel-coated trans-
well chambers. U87 cells were planted into the chambers
and treated with vehicle control (DMSO), 10 μM, 100 μM
or 200 μM t-AUCB for 24 h. Cells treated with 100 μM or
Fig. 2 t-AUCB inhibits cell migration and invasion. a: wound healing analysis for U251 cells treated with vehicle control (DMSO), 10 μM, 100 μM or
200 μM t-AUCB. b: 100 μM or 200 μM t-AUCB treatment suppresses the scratched cell monolayer healing (**P< 0.01), whereas 10 μM t-AUCB has no effect
(#P> 0.05). c, d: matrigel-coated transwell chambers for cell invasion analysis, U87 cells were planted into the chambers and treated with vehicle control
(DMSO), 10 μM, 100 μM or 200 μM t-AUCB. Cells treated with 100 μM or 200 μM t-AUCB showed a low level of penetration through the membranes
compared with those treated with DMSO or 10 μM t-AUCB (**P< 0.01, #P> 0.05)
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the membranes compared with those treated with DMSO
or 10 μM t-AUCB (Fig. 2c and d).t-AUCB induces cell cycle G1 phase arrest
For cell cycle assay, U251 and U87 cells were treated with
DMSO (vehicle control), 10 μM or 150 μM t-AUCB for
48 h followed by flow cytometric analysis. 150 μM t-AUCB
treated cells exhibited G1 phase proportion increase with S
phase proportion decrease (Fig. 3a and b). Interestingly,
10 μM t-AUCB induces increase of G1 phase percentage,
although it does not induce cell growth inhibition.
To further investigate how t-AUCB regulates cell cycle,
we detected the regulators involved in G1/S phase cell
cycle by western blot. In 150 μM t-AUCB treated cells,
the expression levels of c-Myc, Cdc25A, Cyclin D1,
CDK4 and CDK6, which play key roles in G1-S entry,
were decreased (Fig. 3c). Moreover, DNA replication
factors, MCM3 and MCM7, were found to decrease
in t-AUCB treated cells (Fig. 3d).t-AUCB increases COX-2 expression by Hsp27 activation
Our previous study has demonstrated that acquired Hsp27
activation confers resistance to t-AUCB in glioma cells [15].
Since COX-2 overexpression in gliomas is associated with
poor prognosis [18], we hypothesized that COX-2 may
participate in Hsp27 conferred resistance to t-AUCB. To
test this hypothesis, we detected COX-2 mRNA level by
qRT-PCR and its protein expression by western blot. Our
data demonstrated that, t-AUCB treatment increases COX-
2 expression in both mRNA and protein level (P < 0.01)
(Fig. 4a and b). With the blockage of Hsp27 activation by
p38 MAPK inhibitor SB203580, t-AUCB-induced COX-2
overexpression was partially attenuated (Fig. 4c), indicating
the role of Hsp27 activation in COX-2 increase. To further
investigate the effect of Hsp27 on COX-2 expression, cells
were pretreated with Hsp27 inhibitor quercetin or
Hsp27 siRNA followed by t-AUCB treatment. In cells
without t-AUCB treatment, both Hsp27 protein expres-
sion and its phosphorylation level were suppressed by
quercetin or Hsp27 siRNA, resulting in significant de-
crease of COX-2 expression (Fig. 4d). Interestingly, in
Fig. 3 t-AUCB induces cell cycle G1 phase arrest. a, b: U251 and U87 cells were treated with DMSO (vehicle control), 10 μM or 150 μM t-AUCB for 48 h.
10 μM or 150 μM t-AUCB treated cells exhibited G1 phase proportion increase, 150 μM t-AUCB also induces S phase proportion decrease (**P< 0.01,
*P< 0.05, #P> 0.05). c: The expression levels of c-Myc, Cdc25A, Cyclin D1, CDK4 and CDK6 were decreased in 150 μM treated cells. d: The expression levels
of MCM3 and MCM7 were decreased in 150 μM treated cells. β-actin served as loading control. The protein intensity of the immunoblotting band was
quantified by ImageJ and represented by the relative value compare with loading control (1.00)
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COX-2 and Hsp27 expression and Hsp27 phosphoryl-
ation was partially reversed (Fig. 4d).
Quercetin strengthens t-AUCB-induced cell growth inhibition
by inhibition of Hsp27 and COX-2
Since either inhibition of Hsp27 or COX-2 has been re-
ported to facilitate glioma cell death [18–20], we then
investigate whether quercetin, which inhibits both Hsp27
and COX-2 expression, could strengthens t-AUCB-induced
cell growth inhibition. U87 and U251 cells were separately
treated with vehicle control, 5 μM, 15 μM, 30 μM, 60 μM
quercetin, 200 μM t-AUCB, or 200 μM t-AUCB plus
15 μM, 30 μM or 60 μM quercetin for 48 h. Cell growth
was tested using CCK-8 kit. As the results shown in
Fig. 5a, quercetin inhibits cell growth in concentration-
depended manner since 15 μM, and strengthens t-AUCB
induced cell growth inhibition. Moreover, the treatment of
t-AUCB plus quercetin behaved more efficiently than quer-
cetin alone (P < 0.01), indicating that t-AUCB can also
strengthen quercetin-induced cell death. To further deter-
mine the role of Hsp27 or COX-2 in cell growth inhibition,
synthetic siRNA was transfected into cells to knockdownexpression of Hsp27 or COX-2. Given the downregulation
of Hsp27 or COX-2, t-AUCB induces more intense cell
death (P < 0.01) (Fig. 5b). Interestingly, it seemed that cells
with knockdown of Hsp27 are more sensitive to t-AUCB
than those with knockdown of COX-2 (P < 0.05).
These results demonstrated that quercetin sensitizes
cells to t-AUCB by downregulation of Hsp27 and
COX-2.
Our previous study has reported that t-AUCB induces
no significant cell apoptosis in U87 and U251 cells
because of Hsp27 conferred resistance [15]. Herein, we
investigated whether quercetin could reverse the apop-
tosis resistance by Hsp27 inhibition. U87 cells were
treated with vehicle control, 200 μM t-AUCB, 30 μM
quercetin or 200 μM t-AUCB plus 30 μM quercetin for
48 h. Cell apoptosis was analyzed using flow cytometer.
As the results shown in Fig. 5c and d, in DMSO (vehicle
control) treated cells the apoptosis proportion (Low
Right and Upper Right section) was 4.51 ± 0.69 %. Cells
treated with 200 μM t-AUCB exhibited no increase in
apoptosis proportion of 5.62 ± 1.48 % (P > 0.05). Cells
treated with 30 μM quercetin also exhibited no increase
in apoptosis proportion of 6.35 ± 1.55 % (P > 0.05). For
Fig. 4 t-AUCB increases COX-2 expression by Hsp27 activation. 200 μM t-AUCB treatment increases COX-2 mRNA expression (a) (**P< 0.01) and protein
expression (b). c: t-AUCB-induced COX-2 overexpression and Hsp27 phosphorylation was partially attenuated by SB203580. d: Hsp27 protein expression
and its phosphorylation and COX-2 expression level were suppressed by quercetin or Hsp27 siRNA in cells without t-AUCB treatment. In cells treated with
quercetin plus t-AUCB, decrease of COX-2 and Hsp27 expression and Hsp27 phosphorylation was partially reversed. β-actin served as loading control. The
protein intensity of the immunoblotting band was quantified by ImageJ and represented by the relative value compare with loading control (1.00)
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:61 Page 7 of 11cells treated with 30 μM quercetin plus 200 μM t-AUCB,
the apoptosis proportion was significantly increased into
16.38 ± 1.53 % (P < 0.01). The caspase-3 activity was also
tested in different treated cells, as the data shown, t-AUCB
plus quercetin significantly increases the activity of caspase-
3 (P < 0.01) (Fig. 5e).
Quercetin sensitizes glioblastoma to t-AUCB treatment
in vivo
To investigate the therapeutic effects of quercetin and
t-AUCB on glioblastoma growth in vivo, we developed
a mouse xenograft model of human glioblastoma by sub-
cutaneously transplanting U87 cells in BALB/c nude mice.
Once tumors grow to 2-4 mm in diameter, the treatment
with quercetin or/and t-AUCB was administered as de-
scribed in Materials and Methods section. The volume of
xenograft tumor was measured and compared between
different groups every two days up to 14 days. As the
results shown in Fig. 6a and b, t-AUCB has no effect on
tumor growth (P > 0.05). t-AUCB plus quercetin treatment
exhibits significant tumor inhibition, compared with con-
trol group (P < 0.01), t-AUCB alone group (P < 0.01) or
quercetin treatment group (P < 0.05). Moreover, the weightof each tumor block was measured. The data confirmed
the results from tumor volume measurement (Fig. 6c). We
then determined the expression of Hsp27, p-Hsp27 and
COX-2 in xenograft tumors with different treatment by
western blot. The levels of Hsp27 phosphorylation and
COX-2 protein were elevated in t-AUCB treated tumors
and sharply decreased in quercetin treated or quercetin
plus t-AUCB treated tumors (Fig. 6d). These results sug-
gested that t-AUCB induces no tumor growth inhibition
in vivo, although it inhibits cell growth in vitro. Quercetin,
a Hsp27 inhibitor, sensitizes glioblastoma to t-AUCB treat-
ment and causes significant tumor inhibition in vivo.
Discussion
We have demonstrated previously that acquired Hsp27
activation by p38 MAPK/MAPKAPK2/Hsp27 signaling
cascade confers apoptosis-resistance to t-AUCB treatment
in glioblastoma cells, although the cell proliferation inhib-
ition and cell cycle G1 phase arrest induced by t-AUCB
were significant [15]. Actually, in the present study, we
further demonstrated that t-AUCB suppresses not only cell
proliferation but also cell migration and invasion, as well as
the expression of cell cycle G1/S transition factors
Fig. 5 Quercetin strengthens t-AUCB-induced cell growth inhibition by inhibition of Hsp27 and COX-2. a: CCK-8 assay for cell viability. U87 and
U251 cells were separately treated with vehicle control (DMSO), 5 μM, 15 μM, 30 μM, 60 μM quercetin, 200 μM t-AUCB, or 200 μM t-AUCB plus
15 μM, 30 μM or 60 μM quercetin for 48 h. The OD values represented the cell viability. Quercetin inhibits cell growth in concentration-depended
manner since 15 μM, and strengthens t-AUCB induced cell growth inhibition. t-AUCB also strengthens quercetin-induced cell death (*P< 0.05, **P< 0.01).
Q: Quercetin; t: t-AUCB. b: CCK-8 assay for cell viability. In U87 and U251 cells, knockdown of Hsp27 or COX-2 strengthens t-AUCB-induced cell growth
inhibition (*P< 0.05, **P< 0.01). siHsp27: Hsp27 siRNA; siCOX-2: COX-2 siRNA; t: t-AUCB. c, d: Cell apoptosis analysis for U87 cells treated with vehicle control,
200 μM t-AUCB, 30 μM quercetin or 200 μM t-AUCB plus 30 μM quercetin for 48 h. Vehicle control treated cells the apoptosis proportion (Low Right and
Upper Right section) was 4.51 ± 0.69 %. Cells treated with 200 μM t-AUCB exhibited no increase in apoptosis proportion of 5.62 ± 1.48 % (P> 0.05). Cells
treated with 30 μM quercetin also exhibited no increase in apoptosis proportion of 6.35 ± 1.55 % (P> 0.05). For cells treated with 30 μM quercetin plus
200 μM t-AUCB, the apoptosis proportion was significantly increased into 16.38 ± 1.53 % (**P< 0.01). Q: Quercetin; t: t-AUCB. e: The caspase-3 activity assay
for U87 cells treated with vehicle control, 200 μM t-AUCB, 30 μM quercetin or 200 μM t-AUCB plus 30 μM quercetin. OD value represented the caspase-3
activity (*P< 0.05, **P< 0.01). Q: Quercetin; t: t-AUCB
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of t-AUCB on glioblastoma cells are complicated with the
concomitance of cytotoxicity and anti-cytotoxicity. Zhang
et al. recently demonstrated that high-dose t-AUCB
(10 mg · kg−1 · d−1) increases primary tumor growth and
metastasis by stimulating tumor angiogenesis and VEGFlevels, whereas low dose t-AUCB, 1 mg · kg−1 · d−1 or 3 mg ·
kg−1 · d−1, inhibits Lewis lung carcinoma metastasis or has
no effect on primary tumor growth and metastasis, which
makes the effects of t-AUCB on tumors more and more
complicated [16]. sEHIs are considered to stimulate
primary tumor growth and metastasis via EETs protection
Fig. 6 Quercetin sensitizes glioblastoma to t-AUCB treatment in vivo. a: Tumor bearing mice were differently treated and the tumor volumes
were measured (*P < 0.05, **P < 0.01). b: xenograft tumors retrieved from animals. c: The weight of each tumor block was measured (*P < 0.05,
**P < 0.01). d: The expression of Hsp27, p-Hsp27 and COX-2 in xenograft tumors by western blot. β-actin served as loading control. The protein
intensity of the immunoblotting band was quantified by ImageJ and represented by the relative value compare with loading control (1.00)
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morigenic effects [21, 22]. However, COX-2 inhibition has
been shown to inhibit VEGF production, indicating that
EETs-induced angiogenesis and tumorigenesis may be
reduced or eliminated by inhibition of COX-2 [23]. More-
over, sEHIs may further sensitize the anti-inflammatory and
antiangiogenic effects of COX-2 inhibition [13, 16]. Zhang
et al. then demonstrated that the combination of t-AUCB
and COX-2 inhibitor synergistically inhibits primary tumor
growth and metastasis, although t-AUCB alone has no
tumor inhibitory effect [16]. Previously, we have demon-
strated similar results that combination of t-AUCB and in-
hibitor of Hsp27 phosphorylation effectively induced cell
apoptosis and synergistically inhibits cell growth in vitro.
Thus, we hypothesized that COX-2 and Hsp27 may inter-
actively participate in conferring resistance to t-AUCB.
Our present data revealed that t-AUCB increases COX-2
expression by Hsp27 activation which is partially reversed
by SB203580, a p38 MAPK inhibitor. Then, quercetin or
Hsp27 specific siRNA was pretreated to inhibit Hsp27expression before t-AUCB treatment. Decreased Hsp27 ex-
pression and activation resulted in significant decrease of
COX-2 expression in cells without t-AUCB treatment,
whereas Hsp27 expression and activation and COX-2 ex-
pression were partially suppressed by quercetin in t-AUCB
treated cells. These results suggested that quercetin sup-
presses Hsp27 and COX-2 expression but t-AUCB partially
reverse quercetin-induced Hsp27 and COX-2 suppression.
However, combination of quercetin and t-AUCB induces
significant cell apoptosis and more efficient cell growth
inhibition than each alone (Fig. 5), although cells treated
with quercetin alone show the least expression of Hsp27
and COX-2. It seems that the increased Hsp27 activation
and COX-2 expression contribute to acquire resistance to
t-AUCB treatment, and quercetin partially reverses the re-
sistance by Hsp27 and COX-2 inhibition. The combination
of quercetin and t-AUCB was also demonstrated to signifi-
cantly inhibit glioblastoma growth in vivo from our data
(Fig. 6). Although t-AUCB alone has no effect on xenograft
glioblastoma, quercetin reverses the resistance of tumors
Li et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:61 Page 10 of 11to t-AUCB treatment and causes more efficient tumor
growth inhibition than itself alone. Previously, combin-
ation of t-AUCB and Hsp27 phosphorylation inhibitor has
been reported to synergistically inhibit glioblastoma cell
growth in vitro by us [15], and combination of t-AUCB and
COX-2 inhibitor has been shown to synergistically inhibit
primary tumor growth by others [16]. Here we demon-
strated for the first time that combination of t-AUCB and
quercetin with co-inhibition of Hsp27 and COX-2 synergis-
tically inhibits glioblastoma growth in vitro and in vivo.
Few literatures have mentioned the interaction of
Hsp27 and COX-2 in tumors. Lasa, et al. demonstrated
that p38 MAPK/MAPKAPK2/Hsp27 signaling cascade
regulates COX-2 mRNA stability in HeLa cells [24].
They found that COX-2 mRNA is stabilized by the ac-
tivation of p38 MAPK, which is blocked by SB203580,
and that the effects of p38 MAPK are mediated by
phosphorylation of Hsp27 [24]. Our present study
demonstrated similar effect that COX-2 mRNA and
protein expression is increased by Hsp27 activation.
However, it is impossible to apply SB203580 or Hsp27
siRNA in clinical medication; thus, we decided to test
the effects of Hsp27 inhibitor quercetin which had
been studied in clinical trials on in vitro and in vivo
system [25]. Quercetin, a bioflavonoid widely distrib-
uted in plants, is well known as one of the “nature
agents” with antitumor effects [26, 27]. It has been
demonstrated to inhibit Hsp27 and display antitumor
activity in several tumor cells or cancer stem cells,
such as lung cancer stem cells [28], breast cancer stem
cells [29], oral cancer cells [30], hepatoma cells [31],
human Ewing’s tumor cells [32], prostate cancer cells
[27], as well as glioblastoma cells [33]. Our data dem-
onstrated a novel supplementation that quercetin in-
hibits both Hsp27 and COX-2 and eliminates the
resistance to t-AUCB in glioblastoma.Conclusions
Our study demonstrates that t-AUCB inhibits cell prolif-
eration, migration and invasion and induces cell cycle
G1 phase arrest in vitro; increased Hsp27 activation and
following COX-2 overexpression confer resistance to
t-AUCB treatment in glioblastoma in vitro and in vivo;
quercetin sensitizes glioblastoma to t-AUCB by dual in-
hibition of Hsp27 and COX-2. Combination of t-AUCB
and quercetin may be a potential approach to treating
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